

5-Minute Journal Club: New Directions and Approaches in the Management of HER2-Altered Non-Small Cell Lung Cancer — Issue 3

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase II DESTINY-Lung02 study evaluating trastuzumab deruxtecan (T-DXd) for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC) reported which approximate objective response rate for patients receiving the 5.4 mg/kg dose?
 - a. 28%
 - b. 51%
 - c. 74%
2. Which of the following descriptions best represents the study design of the Beamion PANTUMOR-1 clinical trial?
 - a. A Phase Ib dose-escalation and expansion study evaluating the combination of zongertinib with other systemic therapies for HER2-altered solid tumors
 - b. A Phase II, open-label study evaluating zongertinib for multiple solid tumors with HER2 alterations, including HER2 overexpression and amplification
 - c. A Phase III randomized controlled trial comparing zongertinib to standard therapy for treatment-naïve HER2-mutant cancers
3. Which of the following drug descriptions best reflects the mechanism of action of zongertinib?
 - a. Tyrosine kinase inhibitor (TKI) targeting both HER2 and EGFR
 - b. HER2-specific, EGFR-sparing TKI
 - c. Pan-HER TKI
4. Which of the following descriptions best represents the study design of the DESTINY-Lung04 clinical trial?
 - a. An open-label, multiple-arm, dose escalation and expansion Phase I trial evaluating T-DXd as monotherapy and in combination for patients with HER2-overexpressing metastatic NSCLC (mNSCLC)
 - b. A Phase II randomized study evaluating T-DXd for previously treated HER2-mutant mNSCLC
 - c. A Phase III randomized, open-label trial evaluating T-DXd for untreated HER2-mutant mNSCLC